[1] | Dyerberg J, Bang HO. (1970).Lipid metabolism, atherogenesis, and haemostasis in Eskimos: The role of the prostaglandin-3 family. Haemostasis 8(3-5):227-233. |
|
[2] | Eunice Molinar-Toribio1, Jara Pe ´rez-Jime ´nez1, Sara Ramos-Romero, et al. (2015) Effect of n-3 PUFA supplementation at different EPA:DHA ratios on the spontaneously hypertensive obese rat model of the metabolic syndrome. British Journal of Nutrition 113: 878-887 |
|
[3] | WHIMS-MRI. (2014) Higher RBC EPA+DHA corresponds with larger total brain and hippocampal volumes. American Academy of Neurology 82(5):435-42. |
|
[4] | Hajime Ishii, Yasuo Horie, Shigetoshi Ohshima, et al. (2009). Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocytespecific Pten-deficient mice. J Hepatol 50(3):562-71. |
|
[5] | Y.A. Carpentier, L. Portois, W.J. Malaisse. (2006). N-3 fatty acids and the metabolic syndrome. Am. J. Clin. Nutr 83:1499S-1504S. |
|
[6] | G. Schmitz, J. Ecker. (2008). The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 47(2):147-55. |
|
[7] | Kunesova M. (2006). The influence of n-3 polyunsaturated fatty acids and very low calorie diet during a short-term weight reducing regimen on weight loss and serum fatty acid composition in severely obese women. Physiol Res Acad Sci Bohemoslov 55:63-72. |
|
[8] | Thorsdottir I, Tomasson H, Gunnarsdottir I, Gisladottir E, Kiely M, Parra MD, et al. (2007). Randomized trial of weight-loss-diets for young adults varying in fish and fish oil content. Int J Obes 31:1560-1566. |
|
[9] | LeMieux MJ, Kalupahana NS, Scoggin S, Moustaid-Moussa N. (2015) Eicosapentaenoic acid reduces adipocyte hypertrophy and inflammation in diet-induced obese mice in an adiposity-independent manner. J Nutr 145(3):411-7. |
|
[10] | Huerta AE, Navas-Carretero S, et al. (2015) Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss.Obesity (Silver Spring) 23(2):313-21. |
|
[11] | Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. (2006) Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189(1):19-30. |
|
[12] | Jacobson TA. (2008)Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr 87 (Suppl):S1981-S1990. |
|
[13] | Fletcher B, Berra K, Ades P, et al. (2005)Managing abnormal blood lipids: a collaborative approach. Circulation 112:3184-3209. |
|
[14] | Musa-VelosoK, Binns MA, Kocenas AC, et al. (2010) Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependentlyreduce fasting serum triglycerides. Nutr Rev 68(3):155-67. |
|
[15] | Durante W. (2010). Targeting heme oxygenase-1 in vascular disease. Curr Drug Targets 11(12):1504-1516. |
|
[16] | Idriss NK, Blann AD, Lip GY. (2008)Hemoxygenase-1 in cardiovascular disease. J Am Coll Cardiol 52(12):971-978. |
|
[17] | Lee SE, Kim GD, Yang H, Son GW, Park HR, Cho JJ, Ahn HJ, Park CS, Park YS. (2015)Effects of eicosapentaenoic acid (EPA) on the cytoprotection via Nrf2-mediated heme oxygenase-1 inhuman endothelial cells. J Cardiovasc Pharmacol 26. |
|
[18] | H. Chamras, A. Ardashian, D. Heber, J.A. Glaspy. (2002)Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J Nutr Biochem 13:711-717. |
|
[19] | Eser PO, Vanden Heuvel JP, Araujo J, Thompson JT. (2013) Marineand plant-derived omega-3 fatty acids differentially regulate prostate cancer cell proliferation. Mol Clin Oncol 1(3):444-452. |
|
[20] | Fukui M, Kang KS, Okada K , Zhu BT. (2013)EPA, an omega-3fatty acid, induces apoptosis in human pancreatic cancer cells:role of ROS accumulation, caspase-8 activation, and autophagyinduction. J Cell Biochem 114(1):192-203. |
|
[21] | Hossain Z, Hosokawa M, Takahashi K. (2009)Growth inhibition and induction of apoptosis of colon cancer cell lines by applying marine phospholipid. Nutr Cancer 61:123-130. |
|
[22] | B.E.S. Hashem, K.L. Rudolph. (2007)Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. J Gastroenterol 132:2557-2576. |
|
[23] | J. Whang Peng, A.L. Cheng, C. Hsu, C.M. Chen. (2010)Clinical development and future direction for the treatment of hepatocellular carcinoma. J Exp Clin Med 2:93-103. |
|
[24] | Zhang Y, Han L, Qi W, Cheng D, Ma X, Hou L, Cao X, Wang C. (2015) Eicosapentaenoic acid (EPA) induced apoptosis in HepG2 cells through ROS-Ca(2+)-JNK mitochondrial pathways. Biochem Biophys Res Commun 456(4):926-32. |
|
[25] | Fietkau R, Lewitzki V, Kuhnt T, Holscher T, Hess CF, Berger B, Wiegel T, Rodel C, Niewald M, Hermann RM , Lubgan D. (2013)A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: results of a randomized, controlled, multicenter trial. Cancer 119: 3343-3353. |
|
[26] | Mizoguchi K, Ishiguro H, Takahashi H, Sakamoto N, et al. (2014)Induction of apoptosis by eicosapentaenoic acid in esophageal squamous cell carcinoma. Anticancer Res 34(12):7145-9. |
|
[27] | Jump DB. (2002)The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 277: 8755-8758. |
|
[28] | Konuma K, Itoh M, Suganami T, Kanai S, et al. (2015)Eicosapentaenoic Acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. PLoS One 27, 10(3):e0121528. |
|
[29] | Wirth S, Ribes-Koninckx C, Calzado MA, et al. (2010)High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 52:501-7. |
|
[30] | Sokal EM, Bourgois A, Stephenne X, et al. (2010)Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children andadolescents. J Hepatol 52: 827-31. |
|
[31] | Tajiri H, Inui A, Kiyohara Y, et al. (2009)Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology. Eur J Gastroenterol Hepatol 21:1256-60. |
|
[32] | Baker RD, Dee D, Baker SS. (2007) Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. J Clin Gastroenterol 41: 111-4. |
|
[33] | McHutchison JG, Manns MP, Longo DL. (2006)Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 26: 389-98. |
|
[34] | Suzuki M, Inage E, et al. (2012)Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients. Pediatr Int 54(4):528-31. |
|
[35] | Rowan AD. (2001)Cartilage catabolism in arthritis: factors that influence homeostasis. Expert Rev Mol Med 1-20. |
|
[36] | Hashimoto S, Nishiyama T, Hayashi S, et al. (2009)Role of p53 in human chondrocyte apoptosis in response to shear strain. Arthritis Rheum 60:2340-2349. |
|
[37] | Takebe K, Nishiyama T, Hayashi S, et al. (2011)Regulation of p38 MAPK phosphorylation inhibits chondrocyte apoptosis in response to heat stress or mechanical stress. Int J Mol Med 27:329-335. |
|
[38] | Sakata S, Hayashi S, Fujishiro T, et al. (2015)Oxidative Stress-induced Apoptosis and Matrix Loss of Chondrocytes Is Inhibited by Eicosapentaenoic Acid. J Orthop Res 33(3):359-65. |
|
[39] | Jump DB, Depner CM, Tripathy S. (2012)Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res 53:2525–2545. |
|
[40] | Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A. (2009) Benefits of fish oil supplementation in hyperlipidemia: a systematic review and metaanalysis. Int J Cardiol 136(1):4-16. |
|
[41] | Verduci E, Agostoni C, et al. (2014)Blood lipids profile in hyperlipidemic children undergoing different dietary long chain polyunsaturated supplementations: a preliminary clinical trial. Int J Food Sci Nutr 65(3):375-9. |
|
[42] | Angela Pirillo. (2013)Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. Int J Cardiol. |
|